Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

SVB Leerink starts Immatics at OP; PT $17

SVB Leerink initiated coverage of Immatics (NASDAQ:IMTX) with an “outperform” rating and $17 price target. The stock closed at $10.57 on July 24. Immatics is developing T-cell receptor (TCR)-based immunotherapies and...

July 27, 2020

Markets

Dawson James starts OncoSec Medical at buy; PT $10

Dawson James Securities launched coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $3.19 on July 24. OncoSec has developed a plasmid-based vector that is delivered...

July 27, 2020

Markets

BTIG starts new coverage of Precision BioSciences at buy; PT $16

BTIG analyst Thomas Shrader assumed coverage of Precision BioSciences (NASDAQ:DTIL) with a “buy” rating and $16 price target. The stock closed at $7.41 on July 24. “We like Precision Biosciences in the race to develop...

July 27, 2020

Developments

PolarityTE reports positive topline data from diabetic foot ulcer trial

PolarityTE (NASDAQ:PTE) reported positive topline results from its trial evaluating SkinTE for the treatment of diabetic foot ulcers. SkinTE is a human cellular and tissue-based product derived from a patient’s own skin...

July 24, 2020

Developments

miRagen cobomarsen gets FDA orphan drug designation for T-cell lymphoma

miRagen Therapeutics’ (NASDAQ:MGEN) cobomarsen was granted FDA orphan drug designation for the treatment of T-cell lymphoma. Cobomarsen, an inhibitor of microRNA-155, is being evaluated in a Phase 1 and Phase 2 trial...

July 24, 2020

Markets

HCW ups Aravive PT to $26 from $15

H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $26 from $15 after the company announced successful completion of its Phase 1b trial testing AVB-500 in patients with platinum resistant ovarian...

July 23, 2020

Markets

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

July 23, 2020

Executive Moves

Canaccord boosts healthcare investment banking team

Canaccord Genuity named Thomas O’Connor as managing director, co-head of U.S. healthcare investment banking, with long-time partners, Matt Steere and Eugene Rozelman, joining Mr. O’Connor as fellow co-heads of the U.S...

July 23, 2020

Developments

AxoGen completes target enrollment in Phase 3 nerve graft study

AxoGen (NASDAQ:AXGN) completed target enrollment of 220 subjects in its Phase 3 RECON study evaluating its Avance nerve graft in digital nerve injuries. The study will compare AxoGen’s Avance nerve graft with...

July 22, 2020

Developments

FDA accepts Aurinia NDA for voclosporin; agrees to priority review

The FDA accepted for priority review Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) NDA for voclosporin for the treatment of lupus nephritis (LN). The NDA for voclosporin is based on the Phase 3 AURORA and Phase 2 AURA...

July 22, 2020

Developments

9 Meters doses first patients in Phase 1b/2a short bowel syndrome trial

9 Meters Biopharma (NASDAQ:NMTR) dosed the first patients in its Phase 1b/2a clinical trial evaluating NM-002 for the treatment of short bowel syndrome. Short bowel syndrome is a rare, life-threatening disease caused by...

July 21, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Subscribe